Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.
Reading
P J
PJ
Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom.
Luce
A K
AK
McKeith
I G
IG
D000368:Aged; D002219:Carbamates / Q000627:therapeutic use*; D017028:Caregivers / Q000523:psychology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000523:psychology*; D048448:Phenylcarbamates; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology; D000068836:Rivastigmine; D013315:Stress, Psychological; D016896:Treatment Outcome
D002219:Carbamates; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine